Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2020

01-02-2020 | Lymphoma | Images in Hematology

Multiple heterogeneous bone invasions of B lymphoblastic lymphoma with the TCF3/PBX1 fusion gene: a case report

Authors: Eri Okura, Shoji Saito, Takenori Natsume, Daisuke Morita, Miyuki Tanaka, Nobutaka Kiyokawa, Yozo Nakazawa

Published in: International Journal of Hematology | Issue 2/2020

Login to get access

Excerpt

A 5-year-old boy was referred to our department for further evaluation and treatment of right knee pain and gadolinium-enhanced lesions in the right femur and tibia on magnetic resonance imaging (Supple Fig. 1A). He had experienced three prior episodes of intermittent fever and right knee pain. One month before admission, his knee pain began to progressively worsen. …
Appendix
Available only for authorised users
Literature
1.
Sunami S, Sekimizu M, Takimoto T, Mori T, Mitsui T, Fukano R, et al. Prognostic impact of intensified maintenance therapy on children with advanced lymphoblastic lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Pediatr Blood Cancer. 2016;63(3):451–7.CrossRefPubMed
2.
Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Nievelstein RA. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014;41(3):565–74.CrossRefPubMed
3.
Kubota-Tanaka M, Osumi T, Miura S, Tsujimoto H, Imamura T, Nishimura A, et al. B-lymphoblastic lymphoma with TCF3-PBX1 fusion gene. Haematologica. 2019;104:e35–7.CrossRefPubMedPubMedCentral
Metadata
Title
Multiple heterogeneous bone invasions of B lymphoblastic lymphoma with the TCF3/PBX1 fusion gene: a case report
Authors
Eri Okura
Shoji Saito
Takenori Natsume
Daisuke Morita
Miyuki Tanaka
Nobutaka Kiyokawa
Yozo Nakazawa
Publication date
01-02-2020
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 2/2020
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02794-9

Other articles of this Issue 2/2020

International Journal of Hematology 2/2020 Go to the issue

Original Article

Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia

Original Article

RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

Original Article

The D-index is not correlated with invasive fungal infection during the early-post engraftment phase among allogeneic hematopoietic stem cell transplant recipients

Original Article

Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area

Case Report

Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia

Progress in Hematology

The role of calreticulin mutations in myeloproliferative neoplasms
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits